Code
MOG-CEBX-01BZ
Test
Active-Compendium
81218
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2 mL in EDTA tube.<br>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>H&E slide (required) plus paraffin block.</b><br>
<b>Cut Slides:</b> H&E slide (required) plus 5-10 unstained slides cut at 5+ microns.<br>
<b>Note on FFPE:</b> Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.<br>
<b>Note:</b> Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.</p>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>H&E slide (required) plus paraffin block.</b><br>
<b>Cut Slides:</b> H&E slide (required) plus 5-10 unstained slides cut at 5+ microns.<br>
<b>Note on FFPE:</b> Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.<br>
<b>Note:</b> Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.</p>
Flag Active
True
Orderable Test Description
This test uses fragment length analysis to detect CEBPA mutations and internal tandem duplications. Includes SNP genotype reporting at rs34529039, with plasma testing for enhanced sensitivity.
Orderable Turn Around Time
10 Days
Orderable Biomarkers
NY Approved
False
Orderable Biomarkers JSON
{"DNA Sequencing": {"SNVs + Indels": ["CEBPA"]}}
Keywords string
CEBPA , Mutation , Analysis CEBPA Mutation Analysis
Title URL
cebpa-mutation-analysis
Clinical Significance
CCAAT/enhancer-binding protein alpha (CEBPA) mutations are detected in about 7-15% of patients with acute myeloid leukemia (AML). Double (biallelic) mutations are associated with good prognosis in patients with intermediate risk and normal cytogenetics who do not have FLT3-ITD mutations. This test aids in assessing the prognosis of newly diagnosed AML patients with normal or intermediate-risk cytogenetics.
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Please select extract & hold - DNA if specimen hold service is desired.